{"format":{"id":"radioligand","name":"Radioligands","blurb":"A ligand that binds the target, a chelator that holds the metal, and an isotope whose emission does the work; beta emitters travel millimetres, alpha emitters micrometres.","axes":["target","isotope"],"axisLabels":["Target","Isotope"],"components":[{"key":"target","label":"Target"},{"key":"isotope","label":"Isotope"},{"key":"emission","label":"Emission"},{"key":"ligand","label":"Ligand class"},{"key":"chelator","label":"Chelator"}]},"counts":{"approved":7,"development":5,"stopped":0,"unclear":0,"untried":37,"drugs":16,"partial":0,"unresolved":1},"coverage":{"total":17,"full":16,"partial":0,"unresolved":1,"pct":94},"rows":[{"key":"target","id":"psma","name":"PSMA","href":"/targets/psma/"},{"key":"target","id":"sstr2","name":"Somatostatin receptor 2","href":"/targets/sstr2/"},{"key":"target","id":"cd20","name":"CD20","href":"/targets/cd20/"},{"key":"target","id":"fap","name":"FAP","href":"/targets/fap/"},{"key":"target","id":"net","name":"Norepinephrine transporter"},{"key":"target","id":"ptprc","name":"PTPRC","href":"/targets/ptprc/"},{"key":"target","id":"nis","name":"Sodium-iodide symporter (NIS)"}],"cols":[{"key":"isotope","id":"lu-177","name":"Lutetium-177","href":"/isotopes/#lu-177"},{"key":"isotope","id":"ac-225","name":"Actinium-225","href":"/isotopes/#ac-225"},{"key":"isotope","id":"i-131","name":"Iodine-131","href":"/isotopes/#i-131"},{"key":"isotope","id":"pb-212","name":"Lead-212","href":"/isotopes/#pb-212"},{"key":"isotope","id":"ra-223","name":"Radium-223","href":"/isotopes/#ra-223"},{"key":"isotope","id":"sm-153","name":"Samarium-153"},{"key":"isotope","id":"y-90","name":"Yttrium-90","href":"/isotopes/#y-90"}],"cells":[{"a":{"key":"target","id":"psma","name":"PSMA","href":"/targets/psma/"},"b":{"key":"isotope","id":"lu-177","name":"Lutetium-177","href":"/isotopes/#lu-177"},"state":"approved","drugs":[{"id":"lu177-psma-it","name":"177Lu-PSMA-I&T","route":"/drugs/lu177-psma-it/","state":"development","status":"phase-3"},{"id":"pluvicto","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/","state":"approved","status":"approved"}],"counts":{"approved":1,"development":1,"stopped":0,"unclear":0},"parts":{"emission":[{"key":"emission","id":"beta","name":"Beta emitter","href":"/technologies/radioligand-therapy/"}],"ligand":[{"key":"ligand","id":"small-molecule","name":"Small-molecule ligand"}],"chelator":[{"key":"chelator","id":"dotaga","name":"DOTAGA"},{"key":"chelator","id":"dota","name":"DOTA"}]},"evidence":[{"record":"lu177-psma-it","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/lu177-psma-it/"},{"record":"registry:lu177-psma-it","kind":"registry","state":"development","label":"ClinicalTrials.gov: 11 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/lu177-psma-it/#registry"},{"record":"pluvicto","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/pluvicto/"},{"record":"pluvicto","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2022: PSMA+ mCRPC after ARPI and taxane","href":"/drugs/pluvicto/"},{"record":"pluvicto","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2025: PSMA+ mCRPC after ARPI, before chemotherapy","href":"/drugs/pluvicto/"},{"record":"pluvicto","field":"approvals[2]","kind":"approval","state":"approved","label":"US 2026: Label expansion (July 2026)","href":"/drugs/pluvicto/"},{"record":"pluvicto","field":"approvals[3]","kind":"approval","state":"approved","label":"EU 2022: mCRPC post-ARPI and taxane; pre-chemo 2025","href":"/drugs/pluvicto/"},{"record":"pluvicto","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2022","href":"/regulatory/regions/"},{"record":"pluvicto","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2022","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/pluvicto"},{"record":"pluvicto","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2023","href":"https://products.mhra.gov.uk/?search=Pluvicto"},{"record":"pluvicto","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2025","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"pluvicto","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2023","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Pluvicto"},{"record":"nct06894511","field":"status","kind":"trial","state":"development","label":"An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC: phase 2, active","href":"/trials/nct06894511/"},{"record":"nct05682443","field":"status","kind":"trial","state":"development","label":"ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC: phase 1/2, active","href":"/trials/nct05682443/"},{"record":"nct06004661","field":"status","kind":"trial","state":"development","label":"Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function: phase 2, active","href":"/trials/nct06004661/"},{"record":"registry:pluvicto","kind":"registry","state":"development","label":"ClinicalTrials.gov: 22 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/pluvicto/#registry"}],"reasons":[]},{"a":{"key":"target","id":"psma","name":"PSMA","href":"/targets/psma/"},"b":{"key":"isotope","id":"ac-225","name":"Actinium-225","href":"/isotopes/#ac-225"},"state":"development","drugs":[{"id":"aaa817","name":"AAA817","route":"/drugs/aaa817/","state":"development","status":"phase-3"},{"id":"ac225-psma","name":"Actinium-225 PSMA agents","route":"/drugs/ac225-psma/","state":"development","status":"phase-3"},{"id":"fpi-2265","name":"FPI-2265","route":"/drugs/fpi-2265/","state":"development","status":"phase-2"}],"counts":{"approved":0,"development":3,"stopped":0,"unclear":0},"parts":{"emission":[{"key":"emission","id":"alpha","name":"Alpha emitter","href":"/technologies/targeted-alpha-therapy/"}],"ligand":[{"key":"ligand","id":"small-molecule","name":"Small-molecule ligand"}]},"evidence":[{"record":"aaa817","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/aaa817/"},{"record":"nct06780670","field":"status","kind":"trial","state":"development","label":"Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy: phase 2/3, recruiting","href":"/trials/nct06780670/"},{"record":"nct06855277","field":"status","kind":"trial","state":"development","label":"Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC: phase 3, recruiting","href":"/trials/nct06855277/"},{"record":"registry:aaa817","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/aaa817/#registry"},{"record":"ac225-psma","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/ac225-psma/"},{"record":"alphabreak","field":"status","kind":"trial","state":"development","label":"AlphaBreak (FPI-2265) & AcTION (225Ac-PSMA-617): phase 2, active","href":"/trials/alphabreak/"},{"record":"nct07590934","field":"status","kind":"trial","state":"development","label":"Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer: phase 1/2, recruiting","href":"/trials/nct07590934/"},{"record":"fpi-2265","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/fpi-2265/"},{"record":"nct07611110","field":"status","kind":"trial","state":"development","label":"AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01): phase 3, recruiting","href":"/trials/nct07611110/"},{"record":"nct06909825","field":"status","kind":"trial","state":"development","label":"FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC): phase 2, active","href":"/trials/nct06909825/"},{"record":"nct07590934","field":"status","kind":"trial","state":"development","label":"Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer: phase 1/2, recruiting","href":"/trials/nct07590934/"},{"record":"nct05219500","field":"status","kind":"trial","state":"development","label":"Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).: phase 2, active","href":"/trials/nct05219500/"},{"record":"registry:fpi-2265","kind":"registry","state":"development","label":"ClinicalTrials.gov: 5 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/fpi-2265/#registry"}],"reasons":[]},{"a":{"key":"target","id":"psma","name":"PSMA","href":"/targets/psma/"},"b":{"key":"isotope","id":"ra-223","name":"Radium-223","href":"/isotopes/#ra-223"},"state":"approved","drugs":[{"id":"radium-223","name":"Radium-223 dichloride","route":"/drugs/radium-223/","state":"approved","status":"approved"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{"emission":[{"key":"emission","id":"alpha","name":"Alpha emitter","href":"/technologies/targeted-alpha-therapy/"}],"ligand":[{"key":"ligand","id":"bone-seeker","name":"Bone-seeking mimetic"}]},"evidence":[{"record":"radium-223","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/radium-223/"},{"record":"radium-223","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2013: Symptomatic bone-metastatic CRPC without visceral disease","href":"/drugs/radium-223/"},{"record":"radium-223","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2013","href":"/regulatory/regions/"},{"record":"radium-223","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2013","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/xofigo"},{"record":"radium-223","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2013","href":"https://products.mhra.gov.uk/?search=Xofigo"},{"record":"radium-223","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2016","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"radium-223","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2020","href":"https://english.nmpa.gov.cn/"},{"record":"radium-223","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2014","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Xofigo"},{"record":"registry:radium-223","kind":"registry","state":"development","label":"ClinicalTrials.gov: 9 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/radium-223/#registry"}],"reasons":[]},{"a":{"key":"target","id":"psma","name":"PSMA","href":"/targets/psma/"},"b":{"key":"isotope","id":"sm-153","name":"Samarium-153"},"state":"approved","drugs":[{"id":"samarium-153-lexidronam","name":"Samarium-153 lexidronam","route":"/drugs/samarium-153-lexidronam/","state":"approved","status":"approved"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{"emission":[{"key":"emission","id":"beta","name":"Beta emitter","href":"/technologies/radioligand-therapy/"}],"ligand":[{"key":"ligand","id":"bone-seeker","name":"Bone-seeking mimetic"}],"chelator":[{"key":"chelator","id":"edtmp","name":"EDTMP"}]},"evidence":[{"record":"samarium-153-lexidronam","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/samarium-153-lexidronam/"},{"record":"samarium-153-lexidronam","field":"approvals[0]","kind":"approval","state":"approved","label":"US 1997: Relief of pain in patients with confirmed osteoblastic metastatic bone lesions that enhance on radionuclide bone scan","href":"/drugs/samarium-153-lexidronam/"},{"record":"samarium-153-lexidronam","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 1998: Relief of bone pain from multiple painful osteoblastic skeletal metastases (Quadramet)","href":"/drugs/samarium-153-lexidronam/"},{"record":"samarium-153-lexidronam","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 1998","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/quadramet"},{"record":"registry:samarium-153-lexidronam","kind":"registry","state":"stopped","label":"ClinicalTrials.gov: 2 terminated or withdrawn studies and none active (fetched 2026-09-21)","href":"/drugs/samarium-153-lexidronam/#registry"}],"reasons":[]},{"a":{"key":"target","id":"sstr2","name":"Somatostatin receptor 2","href":"/targets/sstr2/"},"b":{"key":"isotope","id":"lu-177","name":"Lutetium-177","href":"/isotopes/#lu-177"},"state":"approved","drugs":[{"id":"itm-11","name":"177Lu-edotreotide","route":"/drugs/itm-11/","state":"development","status":"phase-3"},{"id":"lutathera","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/","state":"approved","status":"approved"}],"counts":{"approved":1,"development":1,"stopped":0,"unclear":0},"parts":{"emission":[{"key":"emission","id":"beta","name":"Beta emitter","href":"/technologies/radioligand-therapy/"}],"ligand":[{"key":"ligand","id":"peptide","name":"Peptide","href":"/technologies/prrt/"}],"chelator":[{"key":"chelator","id":"dota","name":"DOTA"}]},"evidence":[{"record":"itm-11","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/itm-11/"},{"record":"nct04919226","field":"status","kind":"trial","state":"development","label":"Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE: phase 3, active","href":"/trials/nct04919226/"},{"record":"registry:itm-11","kind":"registry","state":"development","label":"ClinicalTrials.gov: 11 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/itm-11/#registry"},{"record":"lutathera","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/lutathera/"},{"record":"lutathera","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2018: SSTR+ GEP-NETs","href":"/drugs/lutathera/"},{"record":"lutathera","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2024: Paediatric ≥12 years; first-line (NETTER-2 label)","href":"/drugs/lutathera/"},{"record":"lutathera","field":"approvals[2]","kind":"approval","state":"approved","label":"EU 2017: First approval globally (Sep 2017)","href":"/drugs/lutathera/"},{"record":"lutathera","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2018","href":"/regulatory/regions/"},{"record":"lutathera","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2017","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/lutathera"},{"record":"lutathera","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2018","href":"https://products.mhra.gov.uk/?search=Lutathera"},{"record":"lutathera","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2021","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"lutathera","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2024","href":"https://english.nmpa.gov.cn/"},{"record":"lutathera","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2018","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Lutathera"},{"record":"nct05142696","field":"status","kind":"trial","state":"development","label":"A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab: phase 1/2, active","href":"/trials/nct05142696/"},{"record":"action-1","field":"status","kind":"trial","state":"development","label":"ACTION-1: phase 3, recruiting","href":"/trials/action-1/"},{"record":"nct04711135","field":"status","kind":"trial","state":"development","label":"Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs: phase 2, active","href":"/trials/nct04711135/"},{"record":"nct03972488","field":"status","kind":"trial","state":"development","label":"Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET: phase 3, active","href":"/trials/nct03972488/"},{"record":"registry:lutathera","kind":"registry","state":"development","label":"ClinicalTrials.gov: 37 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/lutathera/#registry"}],"reasons":[]},{"a":{"key":"target","id":"sstr2","name":"Somatostatin receptor 2","href":"/targets/sstr2/"},"b":{"key":"isotope","id":"ac-225","name":"Actinium-225","href":"/isotopes/#ac-225"},"state":"development","drugs":[{"id":"ryz101","name":"Actinium-225 DOTATATE","route":"/drugs/ryz101/","state":"development","status":"phase-3"}],"counts":{"approved":0,"development":1,"stopped":0,"unclear":0},"parts":{"emission":[{"key":"emission","id":"alpha","name":"Alpha emitter","href":"/technologies/targeted-alpha-therapy/"}],"ligand":[{"key":"ligand","id":"peptide","name":"Peptide","href":"/technologies/prrt/"}],"chelator":[{"key":"chelator","id":"dota","name":"DOTA"}]},"evidence":[{"record":"ryz101","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/ryz101/"},{"record":"action-1","field":"status","kind":"trial","state":"development","label":"ACTION-1: phase 3, recruiting","href":"/trials/action-1/"},{"record":"nct06590857","field":"status","kind":"trial","state":"development","label":"Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.: phase 1/2, active","href":"/trials/nct06590857/"},{"record":"registry:ryz101","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-21)","href":"/drugs/ryz101/#registry"}],"reasons":[]},{"a":{"key":"target","id":"sstr2","name":"Somatostatin receptor 2","href":"/targets/sstr2/"},"b":{"key":"isotope","id":"pb-212","name":"Lead-212","href":"/isotopes/#pb-212"},"state":"development","drugs":[{"id":"alphamedix","name":"212Pb-DOTAMTATE","route":"/drugs/alphamedix/","state":"development","status":"phase-2"}],"counts":{"approved":0,"development":1,"stopped":0,"unclear":0},"parts":{"emission":[{"key":"emission","id":"alpha","name":"Alpha emitter","href":"/technologies/targeted-alpha-therapy/"}],"ligand":[{"key":"ligand","id":"peptide","name":"Peptide","href":"/technologies/prrt/"}],"chelator":[{"key":"chelator","id":"dota","name":"DOTA"}]},"evidence":[{"record":"alphamedix","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/alphamedix/"},{"record":"registry:alphamedix","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-21)","href":"/drugs/alphamedix/#registry"}],"reasons":[]},{"a":{"key":"target","id":"cd20","name":"CD20","href":"/targets/cd20/"},"b":{"key":"isotope","id":"y-90","name":"Yttrium-90","href":"/isotopes/#y-90"},"state":"approved","drugs":[{"id":"ibritumomab-tiuxetan","name":"Ibritumomab tiuxetan","route":"/drugs/ibritumomab-tiuxetan/","state":"approved","status":"approved"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{"emission":[{"key":"emission","id":"beta","name":"Beta emitter","href":"/technologies/radioligand-therapy/"}],"ligand":[{"key":"ligand","id":"antibody","name":"Antibody","href":"/technologies/radioimmunotherapy/"}]},"evidence":[{"record":"ibritumomab-tiuxetan","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/ibritumomab-tiuxetan/"},{"record":"ibritumomab-tiuxetan","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2002: Relapsed or refractory low-grade, follicular or transformed B-cell NHL including rituximab-refractory follicular lymphoma","href":"/drugs/ibritumomab-tiuxetan/"},{"record":"ibritumomab-tiuxetan","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2009: Consolidation after first-line chemotherapy in previously untreated follicular NHL","href":"/drugs/ibritumomab-tiuxetan/"},{"record":"ibritumomab-tiuxetan","field":"approvals[2]","kind":"approval","state":"approved","label":"EU 2004: Rituximab-relapsed or refractory CD20-positive follicular lymphoma; first-line consolidation added 2008","href":"/drugs/ibritumomab-tiuxetan/"},{"record":"ibritumomab-tiuxetan","field":"regional.EU","kind":"regional","state":"stopped","label":"EMA / European Commission (EU): withdrawn 2024","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/zevalin","quote":"Zevalin authorised 16 Jan 2004; marketing stopped May 2020 (manufacturing) and the authorisation lapsed under the sunset clause 4 Jan 2024"},{"record":"registry:ibritumomab-tiuxetan","kind":"registry","state":"stopped","label":"ClinicalTrials.gov: 26 terminated or withdrawn studies and none active (fetched 2026-09-21)","href":"/drugs/ibritumomab-tiuxetan/#registry"}],"reasons":[{"drugId":"ibritumomab-tiuxetan","drugName":"Ibritumomab tiuxetan","drugRoute":"/drugs/ibritumomab-tiuxetan/","drugState":"approved","record":"ibritumomab-tiuxetan","kind":"regional","label":"EMA / European Commission (EU): withdrawn 2024","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/zevalin","quote":"Zevalin authorised 16 Jan 2004; marketing stopped May 2020 (manufacturing) and the authorisation lapsed under the sunset clause 4 Jan 2024"}]},{"a":{"key":"target","id":"fap","name":"FAP","href":"/targets/fap/"},"b":{"key":"isotope","id":"lu-177","name":"Lutetium-177","href":"/isotopes/#lu-177"},"state":"development","drugs":[{"id":"fap-2286","name":"FAP-2286 (177Lu / 68Ga)","route":"/drugs/fap-2286/","state":"development","status":"phase-2"}],"counts":{"approved":0,"development":1,"stopped":0,"unclear":0},"parts":{"emission":[{"key":"emission","id":"beta","name":"Beta emitter","href":"/technologies/radioligand-therapy/"}],"ligand":[{"key":"ligand","id":"peptide","name":"Peptide","href":"/technologies/prrt/"}],"chelator":[{"key":"chelator","id":"dota","name":"DOTA"}]},"evidence":[{"record":"fap-2286","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/fap-2286/"},{"record":"nct05142696","field":"status","kind":"trial","state":"development","label":"A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab: phase 1/2, active","href":"/trials/nct05142696/"},{"record":"nct04939610","field":"status","kind":"trial","state":"development","label":"A Study of 177Lu-FAP-2286 in Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct04939610/"},{"record":"nct05939414","field":"status","kind":"trial","state":"development","label":"An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.: phase 3, recruiting","href":"/trials/nct05939414/"},{"record":"nct06894511","field":"status","kind":"trial","state":"development","label":"An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC: phase 2, active","href":"/trials/nct06894511/"},{"record":"nct05413850","field":"status","kind":"trial","state":"development","label":"Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection: phase 1/2, recruiting","href":"/trials/nct05413850/"},{"record":"nct07219238","field":"status","kind":"trial","state":"development","label":"Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, o: phase 2/3, recruiting","href":"/trials/nct07219238/"},{"record":"nct06520345","field":"status","kind":"trial","state":"development","label":"The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global): phase 3, recruiting","href":"/trials/nct06520345/"},{"record":"registry:fap-2286","kind":"registry","state":"development","label":"ClinicalTrials.gov: 4 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/fap-2286/#registry"}],"reasons":[]},{"a":{"key":"target","id":"net","name":"Norepinephrine transporter"},"b":{"key":"isotope","id":"i-131","name":"Iodine-131","href":"/isotopes/#i-131"},"state":"approved","drugs":[{"id":"i131-mibg","name":"131I-MIBG (iobenguane I-131) therapy","route":"/drugs/i131-mibg/","state":"approved","status":"established"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{"emission":[{"key":"emission","id":"beta","name":"Beta emitter","href":"/technologies/radioligand-therapy/"}],"ligand":[{"key":"ligand","id":"small-molecule","name":"Small-molecule ligand"}]},"evidence":[{"record":"i131-mibg","field":"status","kind":"drug","state":"approved","label":"Drug record status: established","href":"/drugs/i131-mibg/"},{"record":"i131-mibg","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2018: Iobenguane scan-positive unresectable, locally advanced or metastatic phaeochromocytoma or paraganglioma in patients 12 and older (Azedra, high-specific-activity form; discontinued 2024)","href":"/drugs/i131-mibg/"},{"record":"anbl1531","field":"status","kind":"trial","state":"development","label":"COG ANBL1531: phase 3, active","href":"/trials/anbl1531/"},{"record":"registry:i131-mibg","kind":"registry","state":"development","label":"ClinicalTrials.gov: 3 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/i131-mibg/#registry"}],"reasons":[]},{"a":{"key":"target","id":"ptprc","name":"PTPRC","href":"/targets/ptprc/"},"b":{"key":"isotope","id":"i-131","name":"Iodine-131","href":"/isotopes/#i-131"},"state":"development","drugs":[{"id":"iomab-b","name":"Iomab-B","route":"/drugs/iomab-b/","state":"development","status":"phase-3"}],"counts":{"approved":0,"development":1,"stopped":0,"unclear":0},"parts":{"emission":[{"key":"emission","id":"beta","name":"Beta emitter","href":"/technologies/radioligand-therapy/"}],"ligand":[{"key":"ligand","id":"antibody","name":"Antibody","href":"/technologies/radioimmunotherapy/"}]},"evidence":[{"record":"iomab-b","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/iomab-b/"},{"record":"nct02665065","field":"status","kind":"trial","state":"development","label":"Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia: phase 3, active","href":"/trials/nct02665065/"},{"record":"registry:iomab-b","kind":"registry","state":"development","label":"ClinicalTrials.gov: 3 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/iomab-b/#registry"}],"reasons":[]},{"a":{"key":"target","id":"nis","name":"Sodium-iodide symporter (NIS)"},"b":{"key":"isotope","id":"i-131","name":"Iodine-131","href":"/isotopes/#i-131"},"state":"approved","drugs":[{"id":"radioactive-iodine","name":"Radioactive iodine (I-131)","route":"/drugs/radioactive-iodine/","state":"approved","status":"approved"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{"emission":[{"key":"emission","id":"beta","name":"Beta emitter","href":"/technologies/radioligand-therapy/"}],"ligand":[{"key":"ligand","id":"substrate","name":"Transporter substrate"}]},"evidence":[{"record":"radioactive-iodine","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/radioactive-iodine/"},{"record":"radioactive-iodine","field":"approvals[0]","kind":"approval","state":"approved","label":"US 1951: Hyperthyroidism and thyroid carcinoma (first radiopharmaceutical approval)","href":"/drugs/radioactive-iodine/"},{"record":"radioactive-iodine","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 1951","href":"/regulatory/regions/"},{"record":"radioactive-iodine","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 1990","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/sodium-iodide-131"},{"record":"radioactive-iodine","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 1990","href":"https://products.mhra.gov.uk/?search=Sodium%20iodide%20I-131"},{"record":"radioactive-iodine","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 1990","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"radioactive-iodine","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 1990","href":"https://english.nmpa.gov.cn/"},{"record":"radioactive-iodine","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 1990","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Sodium%20iodide%20I-131"},{"record":"registry:radioactive-iodine","kind":"registry","state":"development","label":"ClinicalTrials.gov: 13 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/radioactive-iodine/#registry"}],"reasons":[]}],"components":{"target":[{"key":"target","id":"psma","name":"PSMA","href":"/targets/psma/","count":7,"drugIds":["lu177-psma-it","aaa817","ac225-psma","fpi-2265","pluvicto","radium-223","samarium-153-lexidronam"],"states":{"approved":3,"development":4,"stopped":0,"unclear":0}},{"key":"target","id":"sstr2","name":"Somatostatin receptor 2","href":"/targets/sstr2/","count":4,"drugIds":["itm-11","alphamedix","ryz101","lutathera"],"states":{"approved":1,"development":3,"stopped":0,"unclear":0}},{"key":"target","id":"cd20","name":"CD20","href":"/targets/cd20/","count":1,"drugIds":["ibritumomab-tiuxetan"],"states":{"approved":1,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"fap","name":"FAP","href":"/targets/fap/","count":1,"drugIds":["fap-2286"],"states":{"approved":0,"development":1,"stopped":0,"unclear":0}},{"key":"target","id":"net","name":"Norepinephrine transporter","count":1,"drugIds":["i131-mibg"],"states":{"approved":1,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"ptprc","name":"PTPRC","href":"/targets/ptprc/","count":1,"drugIds":["iomab-b"],"states":{"approved":0,"development":1,"stopped":0,"unclear":0}},{"key":"target","id":"nis","name":"Sodium-iodide symporter (NIS)","count":1,"drugIds":["radioactive-iodine"],"states":{"approved":1,"development":0,"stopped":0,"unclear":0}}],"isotope":[{"key":"isotope","id":"lu-177","name":"Lutetium-177","href":"/isotopes/#lu-177","count":5,"drugIds":["itm-11","lu177-psma-it","fap-2286","lutathera","pluvicto"],"states":{"approved":2,"development":3,"stopped":0,"unclear":0}},{"key":"isotope","id":"ac-225","name":"Actinium-225","href":"/isotopes/#ac-225","count":4,"drugIds":["aaa817","ryz101","ac225-psma","fpi-2265"],"states":{"approved":0,"development":4,"stopped":0,"unclear":0}},{"key":"isotope","id":"i-131","name":"Iodine-131","href":"/isotopes/#i-131","count":3,"drugIds":["i131-mibg","iomab-b","radioactive-iodine"],"states":{"approved":2,"development":1,"stopped":0,"unclear":0}},{"key":"isotope","id":"pb-212","name":"Lead-212","href":"/isotopes/#pb-212","count":1,"drugIds":["alphamedix"],"states":{"approved":0,"development":1,"stopped":0,"unclear":0}},{"key":"isotope","id":"ra-223","name":"Radium-223","href":"/isotopes/#ra-223","count":1,"drugIds":["radium-223"],"states":{"approved":1,"development":0,"stopped":0,"unclear":0}},{"key":"isotope","id":"sm-153","name":"Samarium-153","count":1,"drugIds":["samarium-153-lexidronam"],"states":{"approved":1,"development":0,"stopped":0,"unclear":0}},{"key":"isotope","id":"y-90","name":"Yttrium-90","href":"/isotopes/#y-90","count":1,"drugIds":["ibritumomab-tiuxetan"],"states":{"approved":1,"development":0,"stopped":0,"unclear":0}}],"emission":[{"key":"emission","id":"beta","name":"Beta emitter","href":"/technologies/radioligand-therapy/","count":10,"drugIds":["i131-mibg","itm-11","lu177-psma-it","fap-2286","ibritumomab-tiuxetan","iomab-b","lutathera","pluvicto","radioactive-iodine","samarium-153-lexidronam"],"states":{"approved":6,"development":4,"stopped":0,"unclear":0}},{"key":"emission","id":"alpha","name":"Alpha emitter","href":"/technologies/targeted-alpha-therapy/","count":6,"drugIds":["alphamedix","aaa817","ryz101","ac225-psma","fpi-2265","radium-223"],"states":{"approved":1,"development":5,"stopped":0,"unclear":0}}],"ligand":[{"key":"ligand","id":"small-molecule","name":"Small-molecule ligand","count":6,"drugIds":["i131-mibg","lu177-psma-it","aaa817","ac225-psma","fpi-2265","pluvicto"],"states":{"approved":2,"development":4,"stopped":0,"unclear":0}},{"key":"ligand","id":"peptide","name":"Peptide","href":"/technologies/prrt/","count":5,"drugIds":["itm-11","alphamedix","ryz101","fap-2286","lutathera"],"states":{"approved":1,"development":4,"stopped":0,"unclear":0}},{"key":"ligand","id":"antibody","name":"Antibody","href":"/technologies/radioimmunotherapy/","count":2,"drugIds":["ibritumomab-tiuxetan","iomab-b"],"states":{"approved":1,"development":1,"stopped":0,"unclear":0}},{"key":"ligand","id":"bone-seeker","name":"Bone-seeking mimetic","count":2,"drugIds":["radium-223","samarium-153-lexidronam"],"states":{"approved":2,"development":0,"stopped":0,"unclear":0}},{"key":"ligand","id":"substrate","name":"Transporter substrate","count":1,"drugIds":["radioactive-iodine"],"states":{"approved":1,"development":0,"stopped":0,"unclear":0}}],"chelator":[{"key":"chelator","id":"dota","name":"DOTA","count":6,"drugIds":["itm-11","alphamedix","ryz101","fap-2286","lutathera","pluvicto"],"states":{"approved":2,"development":4,"stopped":0,"unclear":0}},{"key":"chelator","id":"dotaga","name":"DOTAGA","count":1,"drugIds":["lu177-psma-it"],"states":{"approved":0,"development":1,"stopped":0,"unclear":0}},{"key":"chelator","id":"edtmp","name":"EDTMP","count":1,"drugIds":["samarium-153-lexidronam"],"states":{"approved":1,"development":0,"stopped":0,"unclear":0}}]},"drugs":[{"id":"i131-mibg","name":"131I-MIBG (iobenguane I-131) therapy","route":"/drugs/i131-mibg/","status":"established","modality":"Radioligand therapy (beta, norepinephrine transporter)","state":"approved","confidence":"medium","fields":["mechanism","name","isotope (physics table)","modality"],"components":{"target":{"id":"net","name":"Norepinephrine transporter","href":null,"confidence":"medium","from":["mechanism"],"detail":null},"isotope":{"id":"i-131","name":"Iodine-131","href":"/isotopes/#i-131","confidence":"high","from":["name"],"detail":null},"emission":{"id":"beta","name":"Beta emitter","href":"/technologies/radioligand-therapy/","confidence":"high","from":["isotope (physics table)"],"detail":null},"ligand":{"id":"small-molecule","name":"Small-molecule ligand","href":null,"confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"i131-mibg","field":"status","kind":"drug","state":"approved","label":"Drug record status: established","href":"/drugs/i131-mibg/"},{"record":"i131-mibg","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2018: Iobenguane scan-positive unresectable, locally advanced or metastatic phaeochromocytoma or paraganglioma in patients 12 and older (Azedra, high-specific-activity form; discontinued 2024)","href":"/drugs/i131-mibg/"},{"record":"anbl1531","field":"status","kind":"trial","state":"development","label":"COG ANBL1531: phase 3, active","href":"/trials/anbl1531/"},{"record":"registry:i131-mibg","kind":"registry","state":"development","label":"ClinicalTrials.gov: 3 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/i131-mibg/#registry"}],"reasons":[]},{"id":"itm-11","name":"177Lu-edotreotide","route":"/drugs/itm-11/","status":"phase-3","modality":"Radioligand therapy (beta)","state":"development","confidence":"medium","fields":["targets","name","isotope (physics table)","mechanism","modality"],"components":{"target":{"id":"sstr2","name":"Somatostatin receptor 2","href":"/targets/sstr2/","confidence":"high","from":["targets"],"detail":null},"isotope":{"id":"lu-177","name":"Lutetium-177","href":"/isotopes/#lu-177","confidence":"high","from":["name"],"detail":null},"emission":{"id":"beta","name":"Beta emitter","href":"/technologies/radioligand-therapy/","confidence":"high","from":["isotope (physics table)"],"detail":null},"chelator":{"id":"dota","name":"DOTA","href":null,"confidence":"high","from":["name","mechanism"],"detail":null},"ligand":{"id":"peptide","name":"Peptide","href":"/technologies/prrt/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"itm-11","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/itm-11/"},{"record":"nct04919226","field":"status","kind":"trial","state":"development","label":"Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE: phase 3, active","href":"/trials/nct04919226/"},{"record":"registry:itm-11","kind":"registry","state":"development","label":"ClinicalTrials.gov: 11 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/itm-11/#registry"}],"reasons":[]},{"id":"lu177-psma-it","name":"177Lu-PSMA-I&T","route":"/drugs/lu177-psma-it/","status":"phase-3","modality":"Radioligand therapy (beta)","state":"development","confidence":"medium","fields":["targets","name","isotope (physics table)","mechanism","modality"],"components":{"target":{"id":"psma","name":"PSMA","href":"/targets/psma/","confidence":"high","from":["targets"],"detail":null},"isotope":{"id":"lu-177","name":"Lutetium-177","href":"/isotopes/#lu-177","confidence":"high","from":["name"],"detail":null},"emission":{"id":"beta","name":"Beta emitter","href":"/technologies/radioligand-therapy/","confidence":"high","from":["isotope (physics table)"],"detail":null},"chelator":{"id":"dotaga","name":"DOTAGA","href":null,"confidence":"high","from":["name","mechanism"],"detail":null},"ligand":{"id":"small-molecule","name":"Small-molecule ligand","href":null,"confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"lu177-psma-it","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/lu177-psma-it/"},{"record":"registry:lu177-psma-it","kind":"registry","state":"development","label":"ClinicalTrials.gov: 11 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/lu177-psma-it/#registry"}],"reasons":[]},{"id":"alphamedix","name":"212Pb-DOTAMTATE","route":"/drugs/alphamedix/","status":"phase-2","modality":"Targeted alpha therapy (lead-212)","state":"development","confidence":"medium","fields":["targets","name","isotope (physics table)","mechanism","modality"],"components":{"target":{"id":"sstr2","name":"Somatostatin receptor 2","href":"/targets/sstr2/","confidence":"high","from":["targets"],"detail":null},"isotope":{"id":"pb-212","name":"Lead-212","href":"/isotopes/#pb-212","confidence":"high","from":["name"],"detail":null},"emission":{"id":"alpha","name":"Alpha emitter","href":"/technologies/targeted-alpha-therapy/","confidence":"high","from":["isotope (physics table)"],"detail":null},"chelator":{"id":"dota","name":"DOTA","href":null,"confidence":"high","from":["name","mechanism"],"detail":null},"ligand":{"id":"peptide","name":"Peptide","href":"/technologies/prrt/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"alphamedix","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/alphamedix/"},{"record":"registry:alphamedix","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-21)","href":"/drugs/alphamedix/#registry"}],"reasons":[]},{"id":"aaa817","name":"AAA817","route":"/drugs/aaa817/","status":"phase-3","modality":"radioligand","state":"development","confidence":"medium","fields":["targets","mechanism","isotope (physics table)","modality"],"components":{"target":{"id":"psma","name":"PSMA","href":"/targets/psma/","confidence":"high","from":["targets"],"detail":null},"isotope":{"id":"ac-225","name":"Actinium-225","href":"/isotopes/#ac-225","confidence":"high","from":["mechanism"],"detail":null},"emission":{"id":"alpha","name":"Alpha emitter","href":"/technologies/targeted-alpha-therapy/","confidence":"high","from":["isotope (physics table)"],"detail":null},"ligand":{"id":"small-molecule","name":"Small-molecule ligand","href":null,"confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"aaa817","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/aaa817/"},{"record":"nct06780670","field":"status","kind":"trial","state":"development","label":"Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy: phase 2/3, recruiting","href":"/trials/nct06780670/"},{"record":"nct06855277","field":"status","kind":"trial","state":"development","label":"Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC: phase 3, recruiting","href":"/trials/nct06855277/"},{"record":"registry:aaa817","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/aaa817/#registry"}],"reasons":[]},{"id":"ryz101","name":"Actinium-225 DOTATATE","route":"/drugs/ryz101/","status":"phase-3","modality":"Targeted alpha therapy","state":"development","confidence":"medium","fields":["targets","name","isotope (physics table)","mechanism","modality"],"components":{"target":{"id":"sstr2","name":"Somatostatin receptor 2","href":"/targets/sstr2/","confidence":"high","from":["targets"],"detail":null},"isotope":{"id":"ac-225","name":"Actinium-225","href":"/isotopes/#ac-225","confidence":"high","from":["name"],"detail":null},"emission":{"id":"alpha","name":"Alpha emitter","href":"/technologies/targeted-alpha-therapy/","confidence":"high","from":["isotope (physics table)"],"detail":null},"chelator":{"id":"dota","name":"DOTA","href":null,"confidence":"high","from":["name","mechanism"],"detail":null},"ligand":{"id":"peptide","name":"Peptide","href":"/technologies/prrt/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"ryz101","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/ryz101/"},{"record":"action-1","field":"status","kind":"trial","state":"development","label":"ACTION-1: phase 3, recruiting","href":"/trials/action-1/"},{"record":"nct06590857","field":"status","kind":"trial","state":"development","label":"Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.: phase 1/2, active","href":"/trials/nct06590857/"},{"record":"registry:ryz101","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-21)","href":"/drugs/ryz101/#registry"}],"reasons":[]},{"id":"ac225-psma","name":"Actinium-225 PSMA agents","route":"/drugs/ac225-psma/","status":"phase-3","modality":"Targeted alpha therapy","state":"development","confidence":"medium","fields":["targets","name","isotope (physics table)","modality","mechanism"],"components":{"target":{"id":"psma","name":"PSMA","href":"/targets/psma/","confidence":"high","from":["targets"],"detail":null},"isotope":{"id":"ac-225","name":"Actinium-225","href":"/isotopes/#ac-225","confidence":"high","from":["name"],"detail":null},"emission":{"id":"alpha","name":"Alpha emitter","href":"/technologies/targeted-alpha-therapy/","confidence":"high","from":["isotope (physics table)"],"detail":null},"ligand":{"id":"small-molecule","name":"Small-molecule ligand","href":null,"confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"ac225-psma","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/ac225-psma/"},{"record":"alphabreak","field":"status","kind":"trial","state":"development","label":"AlphaBreak (FPI-2265) & AcTION (225Ac-PSMA-617): phase 2, active","href":"/trials/alphabreak/"},{"record":"nct07590934","field":"status","kind":"trial","state":"development","label":"Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer: phase 1/2, recruiting","href":"/trials/nct07590934/"}],"reasons":[]},{"id":"fap-2286","name":"FAP-2286 (177Lu / 68Ga)","route":"/drugs/fap-2286/","status":"phase-2","modality":"Theranostic pair (peptide radioligand)","state":"development","confidence":"medium","fields":["targets","name","isotope (physics table)","mechanism","modality"],"components":{"target":{"id":"fap","name":"FAP","href":"/targets/fap/","confidence":"high","from":["targets"],"detail":null},"isotope":{"id":"lu-177","name":"Lutetium-177","href":"/isotopes/#lu-177","confidence":"high","from":["name"],"detail":null},"emission":{"id":"beta","name":"Beta emitter","href":"/technologies/radioligand-therapy/","confidence":"high","from":["isotope (physics table)"],"detail":null},"chelator":{"id":"dota","name":"DOTA","href":null,"confidence":"high","from":["name","mechanism"],"detail":null},"ligand":{"id":"peptide","name":"Peptide","href":"/technologies/prrt/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"fap-2286","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/fap-2286/"},{"record":"nct05142696","field":"status","kind":"trial","state":"development","label":"A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab: phase 1/2, active","href":"/trials/nct05142696/"},{"record":"nct04939610","field":"status","kind":"trial","state":"development","label":"A Study of 177Lu-FAP-2286 in Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct04939610/"},{"record":"nct05939414","field":"status","kind":"trial","state":"development","label":"An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.: phase 3, recruiting","href":"/trials/nct05939414/"},{"record":"nct06894511","field":"status","kind":"trial","state":"development","label":"An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC: phase 2, active","href":"/trials/nct06894511/"},{"record":"nct05413850","field":"status","kind":"trial","state":"development","label":"Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection: phase 1/2, recruiting","href":"/trials/nct05413850/"},{"record":"nct07219238","field":"status","kind":"trial","state":"development","label":"Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, o: phase 2/3, recruiting","href":"/trials/nct07219238/"},{"record":"nct06520345","field":"status","kind":"trial","state":"development","label":"The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global): phase 3, recruiting","href":"/trials/nct06520345/"},{"record":"registry:fap-2286","kind":"registry","state":"development","label":"ClinicalTrials.gov: 4 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/fap-2286/#registry"}],"reasons":[]},{"id":"fpi-2265","name":"FPI-2265","route":"/drugs/fpi-2265/","status":"phase-2","modality":"radioligand","state":"development","confidence":"medium","fields":["targets","mechanism","isotope (physics table)","modality"],"components":{"target":{"id":"psma","name":"PSMA","href":"/targets/psma/","confidence":"high","from":["targets"],"detail":null},"isotope":{"id":"ac-225","name":"Actinium-225","href":"/isotopes/#ac-225","confidence":"high","from":["mechanism"],"detail":null},"emission":{"id":"alpha","name":"Alpha emitter","href":"/technologies/targeted-alpha-therapy/","confidence":"high","from":["isotope (physics table)"],"detail":null},"ligand":{"id":"small-molecule","name":"Small-molecule ligand","href":null,"confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"fpi-2265","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/fpi-2265/"},{"record":"nct07611110","field":"status","kind":"trial","state":"development","label":"AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01): phase 3, recruiting","href":"/trials/nct07611110/"},{"record":"nct06909825","field":"status","kind":"trial","state":"development","label":"FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC): phase 2, active","href":"/trials/nct06909825/"},{"record":"nct07590934","field":"status","kind":"trial","state":"development","label":"Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer: phase 1/2, recruiting","href":"/trials/nct07590934/"},{"record":"nct05219500","field":"status","kind":"trial","state":"development","label":"Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).: phase 2, active","href":"/trials/nct05219500/"},{"record":"registry:fpi-2265","kind":"registry","state":"development","label":"ClinicalTrials.gov: 5 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/fpi-2265/#registry"}],"reasons":[]},{"id":"ibritumomab-tiuxetan","name":"Ibritumomab tiuxetan","route":"/drugs/ibritumomab-tiuxetan/","status":"approved","modality":"Radioimmunotherapy (yttrium-90 labelled anti-CD20 antibody)","state":"approved","confidence":"medium","fields":["targets","mechanism","isotope (physics table)","modality"],"components":{"target":{"id":"cd20","name":"CD20","href":"/targets/cd20/","confidence":"high","from":["targets"],"detail":null},"isotope":{"id":"y-90","name":"Yttrium-90","href":"/isotopes/#y-90","confidence":"high","from":["mechanism"],"detail":null},"emission":{"id":"beta","name":"Beta emitter","href":"/technologies/radioligand-therapy/","confidence":"high","from":["isotope (physics table)"],"detail":null},"ligand":{"id":"antibody","name":"Antibody","href":"/technologies/radioimmunotherapy/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"ibritumomab-tiuxetan","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/ibritumomab-tiuxetan/"},{"record":"ibritumomab-tiuxetan","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2002: Relapsed or refractory low-grade, follicular or transformed B-cell NHL including rituximab-refractory follicular lymphoma","href":"/drugs/ibritumomab-tiuxetan/"},{"record":"ibritumomab-tiuxetan","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2009: Consolidation after first-line chemotherapy in previously untreated follicular NHL","href":"/drugs/ibritumomab-tiuxetan/"},{"record":"ibritumomab-tiuxetan","field":"approvals[2]","kind":"approval","state":"approved","label":"EU 2004: Rituximab-relapsed or refractory CD20-positive follicular lymphoma; first-line consolidation added 2008","href":"/drugs/ibritumomab-tiuxetan/"},{"record":"ibritumomab-tiuxetan","field":"regional.EU","kind":"regional","state":"stopped","label":"EMA / European Commission (EU): withdrawn 2024","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/zevalin","quote":"Zevalin authorised 16 Jan 2004; marketing stopped May 2020 (manufacturing) and the authorisation lapsed under the sunset clause 4 Jan 2024"},{"record":"registry:ibritumomab-tiuxetan","kind":"registry","state":"stopped","label":"ClinicalTrials.gov: 26 terminated or withdrawn studies and none active (fetched 2026-09-21)","href":"/drugs/ibritumomab-tiuxetan/#registry"}],"reasons":[{"drugId":"ibritumomab-tiuxetan","drugName":"Ibritumomab tiuxetan","drugRoute":"/drugs/ibritumomab-tiuxetan/","drugState":"approved","record":"ibritumomab-tiuxetan","kind":"regional","label":"EMA / European Commission (EU): withdrawn 2024","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/zevalin","quote":"Zevalin authorised 16 Jan 2004; marketing stopped May 2020 (manufacturing) and the authorisation lapsed under the sunset clause 4 Jan 2024"}]},{"id":"iomab-b","name":"Iomab-B","route":"/drugs/iomab-b/","status":"phase-3","modality":"Radioimmunotherapy conditioning agent (anti-CD45 antibody labelled with iodine-131)","state":"development","confidence":"medium","fields":["modality","mechanism","isotope (physics table)"],"components":{"target":{"id":"ptprc","name":"PTPRC","href":"/targets/ptprc/","confidence":"medium","from":["modality","mechanism"],"detail":null},"isotope":{"id":"i-131","name":"Iodine-131","href":"/isotopes/#i-131","confidence":"high","from":["modality"],"detail":null},"emission":{"id":"beta","name":"Beta emitter","href":"/technologies/radioligand-therapy/","confidence":"high","from":["isotope (physics table)"],"detail":null},"ligand":{"id":"antibody","name":"Antibody","href":"/technologies/radioimmunotherapy/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"iomab-b","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/iomab-b/"},{"record":"nct02665065","field":"status","kind":"trial","state":"development","label":"Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia: phase 3, active","href":"/trials/nct02665065/"},{"record":"registry:iomab-b","kind":"registry","state":"development","label":"ClinicalTrials.gov: 3 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/iomab-b/#registry"}],"reasons":[]},{"id":"lutathera","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/","status":"approved","modality":"Radioligand therapy (beta)","state":"approved","confidence":"medium","fields":["targets","name","isotope (physics table)","mechanism","modality"],"components":{"target":{"id":"sstr2","name":"Somatostatin receptor 2","href":"/targets/sstr2/","confidence":"high","from":["targets"],"detail":null},"isotope":{"id":"lu-177","name":"Lutetium-177","href":"/isotopes/#lu-177","confidence":"high","from":["name"],"detail":null},"emission":{"id":"beta","name":"Beta emitter","href":"/technologies/radioligand-therapy/","confidence":"high","from":["isotope (physics table)"],"detail":null},"chelator":{"id":"dota","name":"DOTA","href":null,"confidence":"high","from":["name","mechanism"],"detail":null},"ligand":{"id":"peptide","name":"Peptide","href":"/technologies/prrt/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"lutathera","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/lutathera/"},{"record":"lutathera","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2018: SSTR+ GEP-NETs","href":"/drugs/lutathera/"},{"record":"lutathera","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2024: Paediatric ≥12 years; first-line (NETTER-2 label)","href":"/drugs/lutathera/"},{"record":"lutathera","field":"approvals[2]","kind":"approval","state":"approved","label":"EU 2017: First approval globally (Sep 2017)","href":"/drugs/lutathera/"},{"record":"lutathera","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2018","href":"/regulatory/regions/"},{"record":"lutathera","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2017","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/lutathera"},{"record":"lutathera","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2018","href":"https://products.mhra.gov.uk/?search=Lutathera"},{"record":"lutathera","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2021","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"lutathera","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2024","href":"https://english.nmpa.gov.cn/"},{"record":"lutathera","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2018","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Lutathera"},{"record":"nct05142696","field":"status","kind":"trial","state":"development","label":"A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab: phase 1/2, active","href":"/trials/nct05142696/"},{"record":"action-1","field":"status","kind":"trial","state":"development","label":"ACTION-1: phase 3, recruiting","href":"/trials/action-1/"},{"record":"nct04711135","field":"status","kind":"trial","state":"development","label":"Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs: phase 2, active","href":"/trials/nct04711135/"},{"record":"nct03972488","field":"status","kind":"trial","state":"development","label":"Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET: phase 3, active","href":"/trials/nct03972488/"},{"record":"registry:lutathera","kind":"registry","state":"development","label":"ClinicalTrials.gov: 37 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/lutathera/#registry"}],"reasons":[]},{"id":"pluvicto","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/","status":"approved","modality":"Radioligand therapy (beta)","state":"approved","confidence":"medium","fields":["targets","name","isotope (physics table)","mechanism","modality"],"components":{"target":{"id":"psma","name":"PSMA","href":"/targets/psma/","confidence":"high","from":["targets"],"detail":null},"isotope":{"id":"lu-177","name":"Lutetium-177","href":"/isotopes/#lu-177","confidence":"high","from":["name"],"detail":null},"emission":{"id":"beta","name":"Beta emitter","href":"/technologies/radioligand-therapy/","confidence":"high","from":["isotope (physics table)"],"detail":null},"chelator":{"id":"dota","name":"DOTA","href":null,"confidence":"high","from":["name","mechanism"],"detail":null},"ligand":{"id":"small-molecule","name":"Small-molecule ligand","href":null,"confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"pluvicto","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/pluvicto/"},{"record":"pluvicto","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2022: PSMA+ mCRPC after ARPI and taxane","href":"/drugs/pluvicto/"},{"record":"pluvicto","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2025: PSMA+ mCRPC after ARPI, before chemotherapy","href":"/drugs/pluvicto/"},{"record":"pluvicto","field":"approvals[2]","kind":"approval","state":"approved","label":"US 2026: Label expansion (July 2026)","href":"/drugs/pluvicto/"},{"record":"pluvicto","field":"approvals[3]","kind":"approval","state":"approved","label":"EU 2022: mCRPC post-ARPI and taxane; pre-chemo 2025","href":"/drugs/pluvicto/"},{"record":"pluvicto","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2022","href":"/regulatory/regions/"},{"record":"pluvicto","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2022","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/pluvicto"},{"record":"pluvicto","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2023","href":"https://products.mhra.gov.uk/?search=Pluvicto"},{"record":"pluvicto","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2025","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"pluvicto","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2023","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Pluvicto"},{"record":"nct06894511","field":"status","kind":"trial","state":"development","label":"An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC: phase 2, active","href":"/trials/nct06894511/"},{"record":"nct05682443","field":"status","kind":"trial","state":"development","label":"ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC: phase 1/2, active","href":"/trials/nct05682443/"},{"record":"nct06004661","field":"status","kind":"trial","state":"development","label":"Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function: phase 2, active","href":"/trials/nct06004661/"},{"record":"registry:pluvicto","kind":"registry","state":"development","label":"ClinicalTrials.gov: 22 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/pluvicto/#registry"}],"reasons":[]},{"id":"radioactive-iodine","name":"Radioactive iodine (I-131)","route":"/drugs/radioactive-iodine/","status":"approved","modality":"Radiopharmaceutical (beta/gamma emitter, natural uptake)","state":"approved","confidence":"medium","fields":["mechanism","name","isotope (physics table)","modality"],"components":{"target":{"id":"nis","name":"Sodium-iodide symporter (NIS)","href":null,"confidence":"medium","from":["mechanism"],"detail":null},"isotope":{"id":"i-131","name":"Iodine-131","href":"/isotopes/#i-131","confidence":"high","from":["name"],"detail":null},"emission":{"id":"beta","name":"Beta emitter","href":"/technologies/radioligand-therapy/","confidence":"high","from":["isotope (physics table)"],"detail":null},"ligand":{"id":"substrate","name":"Transporter substrate","href":null,"confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"radioactive-iodine","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/radioactive-iodine/"},{"record":"radioactive-iodine","field":"approvals[0]","kind":"approval","state":"approved","label":"US 1951: Hyperthyroidism and thyroid carcinoma (first radiopharmaceutical approval)","href":"/drugs/radioactive-iodine/"},{"record":"radioactive-iodine","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 1951","href":"/regulatory/regions/"},{"record":"radioactive-iodine","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 1990","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/sodium-iodide-131"},{"record":"radioactive-iodine","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 1990","href":"https://products.mhra.gov.uk/?search=Sodium%20iodide%20I-131"},{"record":"radioactive-iodine","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 1990","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"radioactive-iodine","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 1990","href":"https://english.nmpa.gov.cn/"},{"record":"radioactive-iodine","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 1990","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Sodium%20iodide%20I-131"},{"record":"registry:radioactive-iodine","kind":"registry","state":"development","label":"ClinicalTrials.gov: 13 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/radioactive-iodine/#registry"}],"reasons":[]},{"id":"radium-223","name":"Radium-223 dichloride","route":"/drugs/radium-223/","status":"approved","modality":"Targeted alpha therapy (bone-seeking)","state":"approved","confidence":"medium","fields":["summary","name","isotope (physics table)","modality","mechanism"],"components":{"target":{"id":"psma","name":"PSMA","href":"/targets/psma/","confidence":"medium","from":["summary"],"detail":null},"isotope":{"id":"ra-223","name":"Radium-223","href":"/isotopes/#ra-223","confidence":"high","from":["name"],"detail":null},"emission":{"id":"alpha","name":"Alpha emitter","href":"/technologies/targeted-alpha-therapy/","confidence":"high","from":["isotope (physics table)"],"detail":null},"ligand":{"id":"bone-seeker","name":"Bone-seeking mimetic","href":null,"confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"radium-223","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/radium-223/"},{"record":"radium-223","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2013: Symptomatic bone-metastatic CRPC without visceral disease","href":"/drugs/radium-223/"},{"record":"radium-223","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2013","href":"/regulatory/regions/"},{"record":"radium-223","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2013","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/xofigo"},{"record":"radium-223","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2013","href":"https://products.mhra.gov.uk/?search=Xofigo"},{"record":"radium-223","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2016","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"radium-223","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2020","href":"https://english.nmpa.gov.cn/"},{"record":"radium-223","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2014","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Xofigo"},{"record":"registry:radium-223","kind":"registry","state":"development","label":"ClinicalTrials.gov: 9 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/radium-223/#registry"}],"reasons":[]},{"id":"samarium-153-lexidronam","name":"Samarium-153 lexidronam","route":"/drugs/samarium-153-lexidronam/","status":"approved","modality":"Bone-seeking therapeutic radiopharmaceutical (beta emitter)","state":"approved","confidence":"medium","fields":["summary","name","isotope (physics table)","mechanism","modality"],"components":{"target":{"id":"psma","name":"PSMA","href":"/targets/psma/","confidence":"medium","from":["summary"],"detail":null},"isotope":{"id":"sm-153","name":"Samarium-153","href":null,"confidence":"high","from":["name"],"detail":null},"emission":{"id":"beta","name":"Beta emitter","href":"/technologies/radioligand-therapy/","confidence":"high","from":["isotope (physics table)"],"detail":null},"chelator":{"id":"edtmp","name":"EDTMP","href":null,"confidence":"high","from":["name","mechanism"],"detail":null},"ligand":{"id":"bone-seeker","name":"Bone-seeking mimetic","href":null,"confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"samarium-153-lexidronam","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/samarium-153-lexidronam/"},{"record":"samarium-153-lexidronam","field":"approvals[0]","kind":"approval","state":"approved","label":"US 1997: Relief of pain in patients with confirmed osteoblastic metastatic bone lesions that enhance on radionuclide bone scan","href":"/drugs/samarium-153-lexidronam/"},{"record":"samarium-153-lexidronam","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 1998: Relief of bone pain from multiple painful osteoblastic skeletal metastases (Quadramet)","href":"/drugs/samarium-153-lexidronam/"},{"record":"samarium-153-lexidronam","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 1998","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/quadramet"},{"record":"registry:samarium-153-lexidronam","kind":"registry","state":"stopped","label":"ClinicalTrials.gov: 2 terminated or withdrawn studies and none active (fetched 2026-09-21)","href":"/drugs/samarium-153-lexidronam/#registry"}],"reasons":[]}],"unresolved":[{"id":"phosphorus-32","name":"Phosphorus-32 (radiophosphorus)","route":"/drugs/phosphorus-32/","format":"radioligand","modality":"Intravenous radiopharmaceutical (beta emitter; historic)","missing":["target","chelator"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."}],"stopped":[{"drugId":"ibritumomab-tiuxetan","drugName":"Ibritumomab tiuxetan","drugRoute":"/drugs/ibritumomab-tiuxetan/","drugState":"approved","record":"ibritumomab-tiuxetan","kind":"regional","label":"EMA / European Commission (EU): withdrawn 2024","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/zevalin","quote":"Zevalin authorised 16 Jan 2004; marketing stopped May 2020 (manufacturing) and the authorisation lapsed under the sunset clause 4 Jan 2024"}],"proposed":[{"id":"rl-dll3-lutetium-177","format":"radioligand","name":"DLL3 radioligand labelled with lutetium-177","a":"dll3","b":"lu-177","raw":{"a":"dll3","b":"lutetium-177"},"matched":true,"unmatched":[],"rationale":"DLL3 is validated by an approved T-cell engager (tarlatamab) and lutetium-177 by two approved radioligands (pluvicto, lutathera). No corpus product pairs DLL3 with a radionuclide, despite small-cell lung cancer's radiosensitivity and the tumour-restricted antigen. Small-cell lung cancer is the most radiosensitive common solid tumour and DLL3 has no normal-tissue surface expression, so the target-to-background is favourable; low antigen density is the objection, which the crossfire of a beta emitter partly answers.","caveat":"Low DLL3 density and the rapid kinetics of small-cell disease mean an antibody carrier may deliver too little dose too slowly; a fast-clearing fragment or a pre-targeting approach may be required.","status":"clinical evidence","statusLabel":"Clinical evidence","score":{"total":79,"burden":33,"worldDeaths":2214899,"validationA":15,"validationB":15,"plausibility":16},"evidence":[{"label":"Trial: Memorial Sloan Kettering Cancer Center (2025-04-23)","url":"https://clinicaltrials.gov/study/NCT06941480","quote":"The purpose of this study is to find out whether 177Lu-DTPA-SC16.56 is a safe treatment for people with small-cell lung cancer or neuroendocrine prostate cancer","kind":"trial"},{"label":"Trial: Novartis Pharmaceuticals (2025-06-05), neighbouring cell","url":"https://clinicaltrials.gov/study/NCT07006727","quote":"The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \\[225Ac\\]Ac-ETN029 and the safety and imaging properties of \\[111In\\]In-ETN029 in patients aged ≥ 18 years with locally advanced or metastatic DLL3 positive cancers.","kind":"trial","adjacent":true},{"label":"Trial: Molecular Partners AG (2025-12-12), neighbouring cell","url":"https://clinicaltrials.gov/study/NCT07278479","quote":"The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \\[212Pb\\]Pb-MP0712, in patients aged ≥18 years with Small Cell Lung Cancer and other locally advanced or metastatic DLL3 positive tumors.","kind":"trial","adjacent":true},{"label":"Trial: Abdera Therapeutics Inc. (2024-12-16), neighbouring cell","url":"https://clinicaltrials.gov/study/NCT06736418","quote":"The goal of Phase 1a is to gather safety, PK and initial efficacy data for 225Ac-ABD147 to better understand best doses for patients with small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC) of the lung following platinum-based chemotherapy.","kind":"trial","adjacent":true}],"refs":["lutathera","pluvicto","tarlatamab"],"cancers":["sclc","extensive-stage-sclc","prostate-nepc"],"proposedBy":"OnCo open pipeline","on":"2026-09-23"},{"id":"rl-cldn18-2-lutetium-177","format":"radioligand","name":"Claudin 18.2 radioligand labelled with lutetium-177","a":"cldn18-2","b":"lu-177","raw":{"a":"cldn18-2","b":"lutetium-177"},"matched":true,"unmatched":[],"rationale":"Claudin 18.2 is validated by an approved antibody (zolbetuximab) and an approved CAR-T (satricabtagene-autoleucel), and lutetium-177 by two approved radioligands (pluvicto, lutathera). No corpus product pairs Claudin 18.2 with a radionuclide, though the antigen's tumour-selective exposure is the property radioligand targets need. Claudin 18.2 is exposed on cancer cells but hidden in tight junctions of normal stomach, giving a tumour-selective epitope; gastric and pancreatic cancers are moderately radiosensitive, and a nanobody or peptide carrier would give the fast clearance a radioligand needs.","caveat":"Normal gastric mucosa does express Claudin 18.2 at the tight junction; whether a radioligand's crossfire spares it, as a large antibody does, needs to be shown in dosimetry first.","status":"preclinical evidence","statusLabel":"Preclinical","score":{"total":77,"burden":31,"worldDeaths":1127584,"validationA":15,"validationB":15,"plausibility":16},"evidence":[{"label":"Paper: Zeng Z et al. (2023-12-08)","url":"https://doi.org/10.1007/s00259-023-06561-1","quote":"[&lt;sup&gt;177&lt;/sup&gt;Lu]Lu-labeled anti-claudin-18.2 antibody demonstrated radioimmunotherapy potential in gastric cancer mouse xenograft models.","kind":"paper"},{"label":"Paper: Wang X et al. (2026-08-01)","url":"https://doi.org/10.1021/acs.molpharmaceut.6c00113","quote":"Preclinical Evaluation of 177Lu-Labeled Anti-CLDN18.2 VHH-Fc for Radioimmunotherapy in Gastric Cancer.","kind":"paper"}],"refs":["lutathera","pluvicto","satricabtagene-autoleucel","zolbetuximab"],"cancers":["gastric-cldn18-2-positive","gastric","pancreatic"],"proposedBy":"OnCo open pipeline","on":"2026-09-23"},{"id":"rl-her2-lutetium-177","format":"radioligand","name":"HER2 radioligand labelled with lutetium-177","a":"her2","b":"lu-177","raw":{"a":"her2","b":"lutetium-177"},"matched":true,"unmatched":[],"rationale":"HER2 is the corpus's most validated delivery antigen (trastuzumab-deruxtecan, trastuzumab-emtansine, zanidatamab) and lutetium-177 is validated by two approved radioligands (pluvicto, lutathera). No corpus product pairs HER2 with a therapeutic radionuclide, although HER2 imaging tracers already show the antigen can be targeted in vivo. HER2 is a proven delivery target, but a full antibody circulates for weeks and delivers a high marrow dose with lutetium-177; a small HER2-binding scaffold (affibody, nanobody) with fast clearance is the format that would make this work, and HER2 on heart tissue is the safety question.","caveat":"An intact antibody carrier would give too much marrow dose; the proposal requires a small, fast-clearing HER2 binder with kidney retention solved, which is engineering work before any efficacy question.","status":"clinical evidence","statusLabel":"Clinical evidence","score":{"total":75,"burden":31,"worldDeaths":1326278,"validationA":15,"validationB":15,"plausibility":14},"evidence":[{"label":"Trial: Radiopharm Theranostics, Ltd (2025-02-13)","url":"https://clinicaltrials.gov/study/NCT06824155","quote":"This is a first-in-human, Phase 0/1, open-label study of177Lu-RAD202 consisting of an Imaging Period with 177Lu-RAD202im(imaging dose) and a Treatment Period with 177Lu-RAD202tr(treatment dose) to determine the recommended dose(s) for future exploration of 177Lu-RAD202 in participants with HER2 expressing advanced solid tumours.","kind":"trial"},{"label":"Trial: Affibody (2025-07-23)","url":"https://clinicaltrials.gov/study/NCT07081555","quote":"This is a FiH phase 1, open-label, two-stage, randomized trial to assess the safety, tolerability, and biodistribution of \\[177Lu\\]Lu-ABY-271 in subjects with HER2 positive metastatic breast cancer.","kind":"trial"},{"label":"Paper: Liu P et al. (2026-07-17)","url":"https://doi.org/10.1126/sciadv.aee4052","quote":"Using human epidermal growth factor receptor 2 (HER2) as a proof of concept, we developed <sup>177</sup>Lu-DOTA-Fab-ABD, which integrates rapid tumor penetration with albumin-mediated extended circulation, improving tumor dosimetry while reducing off-target radiation.","kind":"paper"}],"refs":["lutathera","pluvicto","trastuzumab-deruxtecan","trastuzumab-emtansine","zanidatamab"],"cancers":["breast-her2-positive","gastric-her2-positive","her2-positive-breast-brain-metastases"],"proposedBy":"OnCo open pipeline","on":"2026-09-23"},{"id":"rl-nectin4-lutetium-177","format":"radioligand","name":"Nectin-4 radioligand labelled with lutetium-177","a":"nectin4","b":"lu-177","raw":{"a":"nectin4","b":"lutetium-177"},"matched":true,"unmatched":[],"rationale":"Nectin-4 is validated by an approved ADC (enfortumab-vedotin) and lutetium-177 by two approved radioligands (pluvicto, lutathera). No corpus product pairs Nectin-4 with a radionuclide, although the antigen's density and restricted expression are the properties the radioligand field selects for. Nectin-4 is highly expressed in urothelial cancer with limited normal-tissue expression apart from skin; a small peptide or bicyclic ligand with fast clearance is the plausible carrier, and skin dose is the toxicity to model.","caveat":"A radioligand needs a small ligand with good tumour retention, which for Nectin-4 is not yet an established chemistry; the first evidence would be a PET tracer showing uptake in patients.","status":"preclinical evidence","statusLabel":"Preclinical","score":{"total":75,"burden":31,"worldDeaths":1354108,"validationA":15,"validationB":15,"plausibility":14},"evidence":[{"label":"Paper: Sun L et al. (2026-03-07)","url":"https://doi.org/10.1186/s12951-026-04253-0","quote":"&lt;sup&gt;68&lt;/sup&gt;Ga/&lt;sup&gt;177&lt;/sup&gt;Lu-labeled nectin4-targeted covalent bicyclic peptide: a novel nectin-4-targeted radioligands for theranostic of urothelial carcinoma.","kind":"paper"},{"label":"Paper: Li D et al. (2026-03-30)","url":"https://doi.org/10.1186/s41181-026-00435-1","quote":"Preliminary biological evaluation of a [&lt;sup&gt;177&lt;/sup&gt;Lu]Lu-labeled peptide targeting Nectin-4.","kind":"paper"},{"label":"Trial: Aktis Oncology, Inc. (2025-06-13), neighbouring cell","url":"https://clinicaltrials.gov/study/NCT07020117","quote":"This is a first-in-human Phase 1b, 2-part, multicenter open-label clinical study to evaluate safety and efficacy of a Nectin-4 radiopharmaceutical (\\[225Ac\\]Ac-AKY-1189) in patients with locally advanced or metastatic solid tumors and to establish the maximum tolerated dose (MTD) or maximum administered dose (MAD) and the recommended Phase 2 dose.","kind":"trial","adjacent":true}],"refs":["enfortumab-vedotin","lutathera","pluvicto"],"cancers":["urothelial","tnbc","pancreatic"],"proposedBy":"OnCo open pipeline","on":"2026-09-23"},{"id":"rl-trop2-lutetium-177","format":"radioligand","name":"TROP2 radioligand labelled with lutetium-177","a":"trop2","b":"lu-177","raw":{"a":"trop2","b":"lutetium-177"},"matched":true,"unmatched":[],"rationale":"TROP2 carries three approved ADCs (sacituzumab-govitecan, datopotamab-deruxtecan, sacituzumab-tirumotecan) and lutetium-177 is validated on two targets (pluvicto, lutathera). No corpus product pairs TROP2 with a radionuclide. TROP2 is broadly expressed on epithelial cancers but also on skin, oesophagus and other normal epithelia, which a radioligand cannot spare as an ADC can through antigen-density thresholds; the case is weaker than for Nectin-4 or PSMA.","caveat":"Normal-tissue TROP2 expression is the objection; a PET tracer study showing tumour-to-background ratios comparable to PSMA would be needed before therapy is credible.","status":"no public evidence","statusLabel":"No public evidence","score":{"total":75,"burden":35,"worldDeaths":3171577,"validationA":15,"validationB":15,"plausibility":10},"evidence":[{"label":"Trial: The First Affiliated Hospital of Xiamen University (2024-01-03), neighbouring cell","url":"https://clinicaltrials.gov/study/NCT06188468","quote":"ImmunoPET Targeting Trophoblast Cell-surface Antigen 2 (Trop-2) in Solid Tumors","kind":"trial","adjacent":true}],"refs":["datopotamab-deruxtecan","lutathera","pluvicto","sacituzumab-govitecan","sacituzumab-tirumotecan"],"cancers":["tnbc","nsclc","urothelial","pancreatic"],"proposedBy":"OnCo open pipeline","on":"2026-09-23"},{"id":"rl-cd20-lutetium-177","format":"radioligand","name":"CD20 radioligand labelled with lutetium-177","a":"cd20","b":"lu-177","raw":{"a":"cd20","b":"lutetium-177"},"matched":true,"unmatched":[],"rationale":"CD20 is validated as a radioimmunotherapy target by an approved yttrium-90 conjugate (ibritumomab-tiuxetan) and lutetium-177 is the most validated therapeutic isotope in the corpus (pluvicto, lutathera). No corpus product pairs CD20 with lutetium-177, although the lutetium infrastructure built for prostate and neuroendocrine cancer now exists in most large centres. CD20 radioimmunotherapy is proven with yttrium-90 (ibritumomab-tiuxetan); lutetium-177's gamma emission allows dosimetry and its shorter beta range spares marrow, so it may revive a modality abandoned for logistics rather than efficacy.","caveat":"Radioimmunotherapy of lymphoma lost to rituximab combinations and bispecifics on convenience, not efficacy; a lutetium-177 CD20 agent would need a defined place, most plausibly consolidation in follicular lymphoma.","status":"no public evidence","statusLabel":"No public evidence","score":{"total":68,"burden":24,"worldDeaths":250679,"validationA":15,"validationB":15,"plausibility":14},"evidence":[{"label":"Trial: Nordic Nanovector (2019-01-16), neighbouring cell","url":"https://clinicaltrials.gov/study/NCT03806179","quote":"This study is a Phase 1b, open-label, single arm dose escalation study of Betalutin followed by rituximab in patients with previously treated follicular lymphoma.","kind":"trial","adjacent":true}],"refs":["ibritumomab-tiuxetan","lutathera","pluvicto"],"cancers":["follicular-lymphoma","dlbcl","marginal-zone-lymphoma"],"proposedBy":"OnCo open pipeline","on":"2026-09-23"},{"id":"rl-psma-iodine-131","format":"radioligand","name":"PSMA radioligand labelled with iodine-131","a":"psma","b":"i-131","raw":{"a":"psma","b":"iodine-131"},"matched":true,"unmatched":[],"rationale":"PSMA is validated by an approved lutetium-177 radioligand (pluvicto) and iodine-131 is the oldest approved therapeutic isotope (radioactive-iodine, i131-mibg). No corpus product pairs PSMA with iodine-131, though the isotope's supply is independent of the reactor bottlenecks the corpus flags for lutetium and actinium (actinium-225-supply). Iodine-131 is cheap and reactor-independent of the lutetium supply chain (therapy-isotope-supply-chain), and its 8-day half-life suits slowly clearing ligands; the gamma emission and long marrow dose are the reasons lutetium is preferred.","caveat":"It would need to show equivalence to lutetium-177 with acceptable marrow dose and radiation-protection burden; the argument is access and cost in countries without lutetium supply rather than efficacy.","status":"clinical evidence","statusLabel":"Clinical evidence","score":{"total":68,"burden":26,"worldDeaths":397430,"validationA":15,"validationB":15,"plausibility":12},"evidence":[{"label":"Trial: Progenics Pharmaceuticals, Inc. (2019-05-07)","url":"https://clinicaltrials.gov/study/NCT03939689","quote":"This clinical trial was done to show whether a radioactive drug (I-131-1095) that binds to prostate-specific membrane antigen (PSMA) is useful in treating metastatic prostate cancer that is positive for PSMA.","kind":"trial"},{"label":"Paper: Yu EY et al. (2026-05-01)","url":"https://doi.org/10.1158/1078-0432.ccr-25-4948","quote":"<h4>Purpose</h4>The phase II ARROW study was designed to evaluate radioligand therapy (RLT) with 131I-LNTH-1095, an iodine-131-labeled small molecule targeting prostate-specific membrane antigen (PSMA), in combination with enzalutamide in subjects with metastatic castration-resistant prostate cancer after progression on prior abiraterone therapy.<h4>Patients and methods</h4>Men ≥18 years with PSMA-positive prostat...","kind":"paper"},{"label":"Paper: Afshar-Oromieh A et al. (2017-03-09)","url":"https://doi.org/10.1007/s00259-017-3665-9","quote":"Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with <sup>131</sup>I-MIP-1095.","kind":"paper"}],"refs":["actinium-225-supply","i131-mibg","pluvicto","radioactive-iodine","therapy-isotope-supply-chain"],"cancers":["prostate-mcrpc"],"proposedBy":"OnCo open pipeline","on":"2026-09-23"},{"id":"rl-psma-lead-212","format":"radioligand","name":"PSMA radioligand labelled with lead-212","a":"psma","b":"pb-212","raw":{"a":"psma","b":"lead-212"},"matched":true,"unmatched":[],"rationale":"PSMA is validated by an approved radioligand (pluvicto) and lead-212 is in phase 2 on SSTR2 (alphamedix), while the corpus actinium-225 PSMA programmes are in phase 3 (aaa817, ac225-psma). No corpus product pairs PSMA with lead-212, an isotope whose generator supply avoids the actinium bottleneck the corpus records (actinium-225-supply). Lead-212's 10.6-hour half-life matches the fast kinetics of small PSMA ligands better than actinium-225's ten days, and it can be produced from generators (alpha-nanogenerators) rather than the scarce actinium supply; the short half-life makes distribution the hard part.","caveat":"A 10.6-hour half-life means the dose must be made close to the patient; the proposal stands or falls on a distribution network, not on the biology.","status":"clinical evidence","statusLabel":"Clinical evidence","score":{"total":68,"burden":26,"worldDeaths":397430,"validationA":15,"validationB":7,"plausibility":20},"evidence":[{"label":"Trial: AdvanCell Pty Limited (2023-02-09)","url":"https://clinicaltrials.gov/study/NCT05720130","quote":"The Phase Ib portion of the study aims to determine the safety and tolerability of escalating doses of \\[212Pb\\]Pb-ADVC001 administered every 6, 4, 2 or 1 week(s) and establish the recommended phase 2 doses (RP2D).","kind":"trial"},{"label":"Trial: ARTBIO Inc. (2025-10-09)","url":"https://clinicaltrials.gov/study/NCT07214961","quote":"This Phase 1 study will evaluate the safety, tolerability, and preliminary effectiveness of AB001, an alpha-emitting radioligand targeting prostate-specific membrane antigen (PSMA), in patients with advanced prostate cancer who are either 177Lu-PSMA naïve or experienced.","kind":"trial"},{"label":"Paper: Høyvik AJK et al. (2025-05-21)","url":"https://doi.org/10.1007/s00259-025-07330-y","quote":"The alpha-emitting radioligand [<sup>212</sup>Pb]Pb-AB001 could offer enhanced treatment by delivering high energy over a short range.","kind":"paper"}],"refs":["aaa817","ac225-psma","actinium-225-supply","alpha-nanogenerators","alphamedix","pluvicto"],"cancers":["prostate-mcrpc"],"proposedBy":"OnCo open pipeline","on":"2026-09-23"},{"id":"rl-cd33-actinium-225","format":"radioligand","name":"CD33 radioligand labelled with actinium-225","a":"cd33","b":"ac-225","raw":{"a":"cd33","b":"actinium-225"},"matched":true,"unmatched":[],"rationale":"CD33 is validated by an approved ADC (gemtuzumab-ozogamicin) and actinium-225 is in phase 3 on PSMA and SSTR2 (aaa817, ryz101). No corpus product pairs CD33 with an alpha emitter, though the corpus already carries a CD45 iodine-131 antibody as transplant conditioning (iomab-b) showing the marrow-targeted radioimmunotherapy route is workable. CD33 is on most AML blasts and alpha particles kill without needing internalisation or cell division, which suits quiescent blasts and low antigen density; marrow toxicity is the design constraint and a transplant-conditioning use is the natural fit (iomab-b uses the same logic with CD45).","caveat":"The place for this agent is probably conditioning before transplant or a bridge to it; as a stand-alone therapy in unfit older patients, cytopenias would compete with the disease.","status":"clinical evidence","statusLabel":"Clinical evidence","score":{"total":64,"burden":25,"worldDeaths":305405,"validationA":15,"validationB":10,"plausibility":14},"evidence":[{"label":"Trial: Actinium Pharmaceuticals (2015-10-15)","url":"https://clinicaltrials.gov/study/NCT02575963","quote":"Establish the MTD of fractionated doses of Lintuzumab-Ac225 in combination with low dose cytosine arabinoside (Low Dose Ara-C, LDAC) (Phase 1 portion) 2.","kind":"trial"},{"label":"Trial: National Cancer Institute (NCI) (2025-03-21)","url":"https://clinicaltrials.gov/study/NCT06888323","quote":"This phase I trial tests the safety, side effects and best dose of lintuzumab-Ac225 for the treatment of patients with high risk myelodysplastic syndrome that has not responded to previous treatment (refractory).","kind":"trial"},{"label":"Paper: Rosenblat TL et al. (2022-05-01)","url":"https://doi.org/10.1158/1078-0432.ccr-21-3712","quote":"<h4>Purpose</h4>The anti-CD33 antibody lintuzumab has modest activity against acute myeloid leukemia (AML).","kind":"paper"}],"refs":["aaa817","gemtuzumab-ozogamicin","iomab-b","ryz101"],"cancers":["aml","aml-older-unfit"],"proposedBy":"OnCo open pipeline","on":"2026-09-23"},{"id":"rl-gprc5d-lutetium-177","format":"radioligand","name":"GPRC5D radioligand labelled with lutetium-177","a":"gprc5d","b":"lu-177","raw":{"a":"gprc5d","b":"lutetium-177"},"matched":true,"unmatched":[],"rationale":"GPRC5D is validated by an approved T-cell engager (talquetamab) and lutetium-177 by two approved radioligands (pluvicto, lutathera). No corpus product pairs GPRC5D with a radionuclide, although its restricted expression is the property that made SSTR2 a good radioligand target. GPRC5D is a GPCR restricted to plasma cells and keratinised tissue, the same target class as SSTR2 that made lutathera possible; myeloma is radiosensitive, but no small-molecule or peptide GPRC5D ligand is known, so the carrier would have to be an antibody fragment.","caveat":"Without a small ligand, an antibody-fragment carrier and its kidney retention are the engineering problems; and the hair, nail and tongue expression that gives talquetamab its toxicity would receive radiation too.","status":"no public evidence","statusLabel":"No public evidence","score":{"total":63,"burden":21,"worldDeaths":121388,"validationA":15,"validationB":15,"plausibility":12},"evidence":[],"refs":["lutathera","pluvicto","talquetamab"],"cancers":["multiple-myeloma"],"proposedBy":"OnCo open pipeline","on":"2026-09-23"},{"id":"rl-cd38-actinium-225","format":"radioligand","name":"CD38 radioligand labelled with actinium-225","a":"cd38","b":"ac-225","raw":{"a":"cd38","b":"actinium-225"},"matched":true,"unmatched":[],"rationale":"CD38 is validated by two approved antibodies (daratumumab, isatuximab) and actinium-225 is in phase 3 on two other targets (aaa817, ryz101). No corpus product pairs CD38 with a therapeutic radionuclide, although the antigen's density and the radiosensitivity of plasma cells make it a natural radioimmunotherapy target. Myeloma is radiosensitive and CD38 is dense on plasma cells; an alpha emitter's 2-3 cell range suits marrow-infiltrating disease, but CD38 on NK cells and the long antibody half-life mean marrow toxicity is the limit, as with any haematological radioimmunotherapy.","caveat":"Daratumumab pre-treatment lowers CD38 on residual cells and free daratumumab in serum would compete for the antigen; timing after antibody washout is a prerequisite for any dose to reach tumour.","status":"clinical evidence","statusLabel":"Clinical evidence","score":{"total":60,"burden":21,"worldDeaths":121388,"validationA":15,"validationB":10,"plausibility":14},"evidence":[{"label":"Trial: City of Hope Medical Center (2022-05-05)","url":"https://clinicaltrials.gov/study/NCT05363111","quote":"This phase I trial tests the safety, side effects, and best dose of actinium Ac 225-DOTA-daratumumab (225Ac-DOTA-daratumumab) in combination with daratumumab and indium In 111-DOTA-daratumumab (111In-DOTA-daratumumab) in treating patients with multiple myeloma that does not respond to treatment (refractory) or that has come back (recurrent).","kind":"trial"},{"label":"Trial: City of Hope Medical Center (2024-03-01)","url":"https://clinicaltrials.gov/study/NCT06287944","quote":"Actinium Ac 225-DOTA-daratumumab combined with fludarabine, melphalan and TMLI may be safe, tolerable, and/or effective as conditioning treatment for donor stem cell transplant in patients with high-risk AML, ALL, and MDS.","kind":"trial"},{"label":"Paper: Alvarez NH et al. (2024-11-03)","url":"https://doi.org/10.1101/2024.11.01.621584","quote":"Targeted Alpha Therapy with [ <sup>225</sup> Ac]Ac-Macropa-Isatuximab for CD38-positive Hematological Malignancies","kind":"paper"}],"refs":["aaa817","daratumumab","isatuximab","ryz101"],"cancers":["multiple-myeloma"],"proposedBy":"OnCo open pipeline","on":"2026-09-23"}],"note":"Every state is derived from the records named in evidence; untried means no medicine in this corpus combines the two parts. Proposed cells are hypotheses from the open pipeline (docs/OPEN-PIPELINE.md), not records of a medicine. CC BY-NC 4.0, attribute Data from OnCo (onco.cc). Not medical advice."}